# US 2023/0407277 A1 · Engineered CRISPR-Cas9 Nucleases with Altered PAM Specificity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407277 A1
- Document ID: US20230407277A1
- Status: Published application
- Kind: A1
- Application number: 18/174,294
- Filed: 2023-02-24
- Published: 2023-12-21
- Earliest claimed: 2017-08-23
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: J. Keith Joung; Benjamin Kleinstiver
- Web page: https://patentgrep.com/patent/US20230407277A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/1029: {transferring groups other than amino-acyl groups (2.3.1)}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/71: containing domain for transcriptional activaation, e.g. VP16
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

## Claims

### Claim at position 1

1-35 (canceled)

### Claim 36

A base editor protein comprising a PAM interacting domain that has mutations at positions corresponding to D1135, S1136, and G1218 of SEQ ID NO:1, wherein the mutation at D1135 is M, the mutation at S1136 is Q, and the mutation at G1218 is K.

### Claim 37 (depends on 36)

The base editor protein of claim 36, further comprising a mutation at position corresponding to E1219 of SEQ ID NO:1.

### Claim 38 (depends on 37)

The base editor protein of claim 37, wherein the mutation at position corresponding to E1219 is S or F.

### Claim 39 (depends on 36)

The base editor protein of claim 36, further comprising:
(i) a mutation at a position corresponding to positions selected from the group consisting of D10, E762, D839, H983, and D986 of SEQ ID NO:1; and/or
(ii) a mutation at position corresponding to H840 or N863 of SEQ ID NO:1.

### Claim 40 (depends on 39)

The base editor of claim 39, wherein the mutations are:
(i) D10A or D10N, and/or
(ii) H840A, H840N, or H840Y.

### Claim 41 (depends on 36)

The base editor protein of claim 36, further comprising a mutation at position corresponding to R1335 of SEQ ID NO:1.

### Claim 42 (depends on 36)

The base editor protein of claim 36, further comprising a mutation at position corresponding to T1337 of SEQ ID NO:1.

### Claim 43 (depends on 36)

The base editor protein of claim 36, further comprising a mutation at position corresponding to E1219 of SEQ ID NO: 1, a mutation at position corresponding to R1335 of SEQ ID NO:1, and a mutation at position corresponding to T1337 of SEQ ID NO:1.

### Claim 44 (depends on 43)

The base editor protein of claim 43, wherein the mutation at position corresponding to E1219 is S or F, the mutation at position corresponding to R1335 is E, and the mutation at position corresponding to T1337 is R.

### Claim 45 (depends on 44)

The base editor protein of claim 44, further comprising a mutation at position corresponding to H840 or N863 of SEQ ID NO:1.

### Claim 46 (depends on 45)

The base editor of claim 45, wherein the mutations are:
(i) D10A or D10N, and/or
(ii) H840A, H840N, or H840Y.

### Claim 47 (depends on 46)

The base editor of claim 46, wherein the mutation is D10A or D10N.

### Claim 48 (depends on 36)

The base editor protein of claim 36, wherein the protein comprises one or more of a nuclear localization sequence, cell penetrating peptide sequence, and/or affinity tag.

### Claim 49 (depends on 36)

The base editor protein of claim 36, wherein the base editor comprises (i) a cytidine deaminase domain or (ii) an adenosine deaminase domain.

### Claim 50 (depends on 49)

The base editor protein of claim 49, wherein the cytidine deaminase domain is selected from the group consisting of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) deaminase; activation-induced cytidine deaminase (AID); and cytosine deaminase acting on tRNA (CDAT).

### Claim 51 (depends on 49)

The base editor protein of claim 49, wherein the adenosine deaminase domain is selected from the group consisting of adenosine deaminase 1 (ADA1), ADA2; adenosine deaminase acting on RNA 1 (ADAR1), ADAR2, ADAR3; adenosine deaminase acting on tRNA 1 (ADAT1), ADAT2, ADAT3; and naturally occurring or engineered tRNA- specific adenosine deaminase (TadA).

### Claim 52 (depends on 36)

The base editor protein of claim 36, comprising an SpCas9 having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 53 (depends on 52)

The base editor protein of claim 52, comprising an SpCas9 having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 54 (depends on 53)

The base editor protein of claim 53, comprising an SpCas9 having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 55 (depends on 36)

A method of altering the genome of a cell, the method comprising expressing in the cell, or contacting the cell with, the base editor of claim 36, and a guide RNA having a region complementary to a selected portion of the genome of the cell.

### Claim 56 (depends on 36)

A method of altering a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with the base editor of claim 36, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule.

### Claim 57 (depends on 36)

A method of editing a nucleotide base in a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with the base editor protein of claim 36, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule.

### Claim 58 (depends on 47)

A method of altering the genome of a cell, the method comprising expressing in the cell, or contacting the cell with, the base editor of claim 47, and a guide RNA having a region complementary to a selected portion of the genome of the cell.

### Claim 59 (depends on 47)

A method of altering a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with the base editor of claim 47, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule.

### Claim 60 (depends on 47)

A method of editing a nucleotide base in a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with the base editor protein of claim 47, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule.
